Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $5.8450 (-0.43%) ($5.8450 - $5.8450) on Wed. Apr. 28, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.98% (three month average) | RSI | 84 | Latest Price | $5.8450(-0.43%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS advances 2% a day on average for past five trading days. | Weekly Trend | ADMS advances 10.3% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) TIP(37%) EWG(33%) EWI(31%) EWP(27%) UNG(25%) | Factors Impacting ADMS price | ADMS will decline at least -2.49% in a week (0% probabilities). UUP(-47%) TLT(-21%) FXI(-19%) XLP(-11%) SPLV(-9%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -2.49% (StdDev 4.98%) | Hourly BBV | 0.1 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $5.66(3.27%) | 10 Day Moving Average | $5.43(7.64%) | 20 Day Moving Average | $5.12(14.16%) | To recent high | -12.2% | To recent low | 16.4% | Market Cap | $165m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |